Point72 (Difc) LTD Replimune Group, Inc. Transaction History
Point72 (Difc) LTD
- $2.81 Trillion
- Q2 2024
A detailed history of Point72 (Difc) LTD transactions in Replimune Group, Inc. stock. As of the latest transaction made, Point72 (Difc) LTD holds 6,325 shares of REPL stock, worth $70,397. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,325Holding current value
$70,397% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding REPL
# of Institutions
153Shares Held
70MCall Options Held
26.7KPut Options Held
28.6K-
Baker Bros. Advisors LP New York, NY10MShares$112 Million1.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.24MShares$103 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA5.56MShares$61.9 Million3.26% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$54.2 Million6.46% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$52.5 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $549M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...